Clinerion and Massive Bio partner to improve cancer patient lives

Share Article

Clinerion, provider of the Patient Network Explorer platform which harnesses patient data from a global hospital network, and Massive Bio, provider of end-to-end patient enrollment services for oncology, partner to improve trial site selection and thereby offer better access for cancer patients to leading-edge clinical trials.

Clinerion offers Massive Bio access to oncology patient insights for site outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer queries anonymized patient data from its international network of partner hospitals to deliver real-world health data insights useful for Massive Bio’s site outreach programs. Clinerion’s ANID technology meanwhile allows authorized clinical trial staff to re-identify patients for screening and inclusion in trials, speeding up patient recruitment.

Massive Bio provides end-to-end patient enrollment technology and services in oncology clinical trials for patients treated at community practices. These services include patient identification/engagement, pre-screening, JIT site activation, and real-world data services. Massive Bio structures medical records, NGS results and clinical trials with its proprietary ontologies and Natural Language Processing (NLP) technology. Massive Bio has also developed machine learning algorithms to pre-screen patients at scale. Moreover, Massive Bio provides value-based compensation to pharmaceutical companies by reducing time-to-market, complexity and costs in oncology clinical trial enrollment.

Clinerion’s Patient Network Explorer renders hospital information systems with different data models, terminologies and ontologies mutually intelligible, allowing users to send a single query to the entire network and receive meaningful, actionable patient data insights. Clinerion’s network today covers 74 M patients in 19 countries around the world.

“With Clinerion’s market leadership outside the US and Massive Bio’s US market leadership in oncology clinical trials, we feel that we form a powerful combination to provide global coverage and serve a global client base which creates significant growth opportunities for both enterprises,” says Selin Kurnaz, PhD, Co-founder and CEO of Massive Bio. “We are excited for the opportunities in front of us.”

“Massive Bio’s specialization in oncology offers a great opportunity for Clinerion to support cancer patients in bringing them access to international clinical research and accelerate the development of next generation medical interventions,” says Ian Rentsch, CEO of Clinerion. “This partnership gives us yet another way to improve patient experience and outcomes.”

About Clinerion
Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
Clinerion website: http://www.clinerion.com
Clinerion’s Patient Network Explorer: http://www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

For more information, please contact:
Le Vin Chin
Director, Head of Marketing & Communications
Clinerion Ltd
Elisabethenanlage 11, 4051 Basel, Switzerland
Tel.: +41 61 865 60 54
media@clinerion.com

About Massive Bio Inc
Massive Bio is an Artificial Intelligence (AI) powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information, to speed up drug development. Massive Bio removes barriers for pre-screening and resolves last mile issues such as site availability or out of pocket cost challenges via escalation to pharmaceutical companies to ensure successful clinical trial enrollment. Massive Bio streamlines patient acquisition, scalable pre-screening, operationalization support and real-world data to connect patients to oncology trials. Massive Bio recently launched a Hub to assemble the largest artificial intelligence enabled Just-in-Time (JIT) precision oncology clinical trial network in the world.
Massive Bio was established in 2014, headquartered in New York, and has a dedicated patient contact, provider support and clinical research center in Newtown, Pennsylvania.
Massive Bio website: http://www.massivebio.com

For more information, please contact:
Selin Kurnaz
Co-founder and CEO
90 West Street #12M, New York, NY, 10006
Tel.: 1-844-627-7246
support@massivebio.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Le Vin Chin
@Clinerion
Follow >
Follow us on
Visit website